Cargando…
Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
OBJECTIVE: Insulin glargine 300 (Gla-300) provides less hypoglycemia risk and more flexibility in injection time. The extent to which these effects translate into improved patient-reported outcomes (PROs) is unknown, and is the subject of this observational study. RESEARCH DESIGN AND METHODS: Adults...
Autores principales: | Wieringa, Thomas H, de Wit, Maartje, Twisk, Jos WR, Snoek, Frank J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169664/ https://www.ncbi.nlm.nih.gov/pubmed/30305908 http://dx.doi.org/10.1136/bmjdrc-2018-000548 |
Ejemplares similares
-
Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022) -
HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019) -
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
por: Danne, Thomas, et al.
Publicado: (2020) -
Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
por: Ly, Trang T., et al.
Publicado: (2014) -
Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial
por: Pittas, Anastassios G., et al.
Publicado: (2014)